- Home
- MYNZ vs VYNE Comparison
MYNZ vs VYNE Comparison
Compare MYNZ & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | VYNE |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 12.5M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MYNZ | VYNE |
|---|---|---|
| Price | $1.20 | $0.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 588.0K | 528.5K |
| Earning Date | 09-26-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $659,935.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.03 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.92 | $0.28 |
| 52 Week High | $8.20 | $2.94 |
Technical Indicators
Market Signals| Indicator | MYNZ | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 58.21 |
| Support Level | $1.15 | $0.56 |
| Resistance Level | $1.37 | $0.57 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 22.12 | 39.90 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.